A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. 75-79”
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
(1994) · Medical Entomology and Zoology · Cited by 4,156
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P. D., & Johanson, J. F. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,080
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 584
Stewart, W. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00701-7 · Cited by 492
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
The Health-Related Quality of Life and Economic Burden of Constipation
Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., & Coyne, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00006 · Cited by 396
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
- 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
- Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43
Cited by
Items 101–200 of 581
Sajid, M. S., Hebbar, M., Baig, M. K., Li, A., & Philipose, Z. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16004 · Cited by 65
“Explicitly, there was no increased incidence of prolongation of the QT interval or bradycardia in the prucalopride group compared to placebo.(45,46) Prucalopride seems to be effective for the management of chronic constipation resistant to conventional laxatives.”
BackgroundResultInfluentialTreatment of dysautonomia associated with Parkinson's disease
Mostile, G., & Jankovic, J. J. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70820-x · Cited by 68
“Prucalopride, another selective high-affinity 5-HT4 receptor agonist, increased bowel frequency in about half of patients with severe chronic constipation treated with 4mg daily, but this agent has not been specifically tested in patients with PD [91].”
BackgroundVigone, B., Caronni, M., Severino, A., Bellocchi, C., Baldassarri, A. R., Fraquelli, M., Montanelli, G., Santaniello, A., & Beretta, L. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1340-y · Cited by 69
“CSBMs throughout the study periods [16, 17].”
Zhang, X., Tian, H., Gu, L., Nie, Y., Ding, C., Ge, X., Yang, B. K., Gong, J., & Li, N. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9229-1 · Cited by 67
“Prucalopride has been reported to be effective in treating chronic constipation over a 12-week duration, with clinical remission rates ranging from 19.5% to 30.9% (Camilleri et al., 2008; Michael et al., 2016; Tack et al., 2009).”
BackgroundInfluentialPiessevaux, H. H., Corazziari, E. S., Rey, E., Simrén, M., Wiechowska–Kozłowska, A., Kerstens, R., Cools, M., Barrett, K., & Levine, A. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12553 · Cited by 63
Self-citationRandomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation
Rao, S. S. C., Quigley, E. M. M., Chey, W. D., Sharma, A., & Lembo, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.013 · Cited by 62
Management of chronic constipation in patients with diabetes mellitus
Prasad, V. G. M., & Abraham, P. (2016) · Indian Journal of Gastroenterology · doi:10.1007/s12664-016-0724-2 · Cited by 69
Sinagra, E., Morreale, G. C., Mohammadian, G., Fusco, G., Guarnotta, V., Tomasello, G., Cappello, F., Rossi, F., Amvrosiadis, G., & Raimondo, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6593 · Cited by 80
Constipation in the Elderly: Management Strategies
Spinzi, G., Amato, A., Imperiali, G., Lenoci, N., Mandelli, G., Paggi, S., Radaelli, F., Terreni, N. M., & Terruzzi, V. (2009) · Drugs & Aging · doi:10.2165/00002512-200926060-00003 · Cited by 67
Childhood constipation: Current status, challenges, and future perspectives
Rajindrajith, S., Devanarayana, N. M., & Benninga, M. A. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i5.385 · Cited by 69
Management of Chronic Constipation in the Elderly
Gallagher, P., O’Mahony, D., & Quigley, E. M. M. (2008) · Drugs & Aging · doi:10.2165/00002512-200825100-00001 · Cited by 65
Review article: new receptor targets for medical therapy in irritable bowel syndrome
CAMILLERI, M. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04153.x · Cited by 55
Self-citationCamilleri, M. (2010) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s8091 · Cited by 69
Self-citationRecent advances in understanding and managing chronic constipation
Prichard, D. O., & Bharucha, A. E. (2018) · F1000Research · doi:10.12688/f1000research.15900.1 · Cited by 54
Efficacy of Synbiotics in Patients with Slow Transit Constipation: A Prospective Randomized Trial
Ding, C., Ge, X., Zhang, X., Tian, H., Wang, H., Gu, L., Gong, J., Zhu, W., & Li, N. (2016) · Nutrients · doi:10.3390/nu8100605 · Cited by 55
“Although there is a wide range of medications, many patients are still dissatisfied with their current treatments, according to the results of a long-term survey, due to insufficient efficacy and some adverse effects [8].”
BackgroundHasler, W. L. (2009) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0058-7 · Cited by 57
Chronic constipation: Update on management
Hayat, U., Dugum, M. F., & Garg, S. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.15141 · Cited by 58
Scintigraphic Biomarkers for Colonic Dysmotility
Camilleri, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.23 · Cited by 54
Self-citationMedical Treatment of Parkinson Disease
Stacy, M. A. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.009 · Cited by 54
“The monoamine oxidase type B (MAO-B) inhibitors may be used as a first line treatment or as adjunctive therapy to levodopa in patients with PD. Blockade of MAO-B delays dopamine metabolism, thereby increasing neurotransmitter concentration in the striatum.13–15 Inhibitors that selectively block MAO-B avoid the potenti…”
InfluentialGong, J., Xie, Z., Zhang, T., Gu, L., Yao, W., Guo, Z., Li, Y., Lü, N., Zhu, W., Li, N., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13557 · Cited by 54
Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment
CHANG, J. Y., & Talley, N. J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.04.008 · Cited by 58
Lei, W., Hung, J., Liu, T., Yi, C., & Chen, C. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13986 · Cited by 53
Andrews, C. N., Woo, M., Buresi, M., Curley, M., Gupta, M., Tack, J., Wilsack, L., & Nasser, Y. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.13958 · Cited by 51
Serotonergic Control of Gastrointestinal Development, Motility, and Inflammation
Najjar, S. A., Hung, L. Y., & Margolis, K. G. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220024 · Cited by 59
Kapeller, J., Möller, D., Lasitschka, F., Autschbach, F., Hovius, R., Rappold, G., Brüss, M., Gershon, M. D., & Niesler, B. (2010) · The Journal of Comparative Neurology · doi:10.1002/cne.22525 · Cited by 61
“This 5-HT4 receptor stimulation facilitates neurotransmission in prokinetic pathways (Liu et al., 2005; Pan and Galligan, 1994; Ren et al., 2008) and probably underlies the successful use of 5-HT4 agonists to treat constipation (Camilleri et al., 2008; Muller-Lissner et al., 2001).”
BackgroundBehavioural and new pharmacological treatments for constipation: getting the balance right
Camilleri, M., & Bharucha, A. E. (2010) · Gut · doi:10.1136/gut.2009.199653 · Cited by 59
Self-citationLiu, B., Wu, J., Yan, S., Zhou, K., He, L., Fang, J., Fu, W., Li, N., Su, T., Sun, J., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001050 · Cited by 52
“CSBMidentifies bowelmovements that fully relieves the subjective discomfort of constipation on top of the objective measure of bowel movement frequency (5,24).”
BackgroundCurrent and future therapies for chronic constipation
Tack, J. F. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.01.005 · Cited by 55
Frampton, J. E. (2009) · Drugs · doi:10.2165/11204000-000000000-00000 · Cited by 55
“In healthy volunteers([24,25,27]) and patients with chronic constipation,([13,28,30,32-35]) treatment with prucalopride significantly increased stool frequency (1,([25,28,30,35]) 2([13,27,32-35]) and 4([13,24,32-34]) mg), improved stool consistency (1,([25,28,30,35]) 2([13,25,27,32,33,35]) and 4([13,24,29,32,33]) mg/d…”
BackgroundInfluentialChronic Constipation: Current Treatment Options
Liu, L. W. (2011) · Canadian Journal of Gastroenterology · doi:10.1155/2011/930108 · Cited by 74
Tack, J., Quigley, E., Camilleri, M., Vandeplassche, L., & Kerstens, R. (2013) · United European Gastroenterology Journal · doi:10.1177/2050640612474651 · Cited by 49
Self-citationCamilleri, M. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01643.x · Cited by 50
Self-citationMarco, M. L., Cunningham, M., Bischoff, S. C., Clarke, G. A., Delzenne, N. M., Lewis, J., Meisel, M., Merenstein, D. J., O’Toole, P. W., Staudacher, H. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01176-x · Cited by 58
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S. J., Greer, K. B., Hanson, B., Harris, L. A., Ko, C. W., et al. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002227 · Cited by 56
Understanding and treating refractory constipation
Bassotti, G., & Blandizzi, C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i2.77 · Cited by 48
Assessment of gene-by-sex interaction effect on bone mineral density
Liu, C.-T., Estrada, K., Yerges-Armstrong, L. M., Amin, N., Εvangelou, Ε., Guo, L., Minster, R. L., Carless, M. A., Kammerer, C. M., Oei, L., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1679 · Cited by 51
Diagnostic criteria in IBS: useful or not?
Mearin, F., & Lacy, B. E. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01992.x · Cited by 44
Current and novel therapeutic options for irritable bowel syndrome management
Camilleri, M., & Andresen, V. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.07.009 · Cited by 53
“Prucalopride is a 5-HT4-receptor agonist that has been extensively studied, including pharmacodynamics and large clinical trials in patients with severe chronic constipation [31–34].”
BackgroundSelf-citationSakai, T., Makino, H., Ishikawa, E., Oishi, K., & Kushiro, A. (2011) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2010.542408 · Cited by 44
“In the clinical trials of pharmaceutical products for chronic constipation, the number of spontaneous CBMs is often used as the primary efficacy endpoint (Kamm et al. 2005, Camilleri et al. 2008, Quigley et al. 2009, Tack et al. 2009).”
MethodTack, J., Camilleri, M., Dubois, D., Vandeplassche, L., Joseph, A., & Kerstens, R. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12505 · Cited by 47
“…used the ITT populations taking prucalopride 2 mg or placebo from three randomized, double-blind, 12-week, phase III trials: the trial reported by Camilleri et al. 2008 was conducted at 38 centers in the USA,9 the trial by Quigley et al. 2008 was conducted at 41 centers in the USA,10 and the…”
MethodSelf-citationClinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
Camilleri, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.261 · Cited by 47
Self-citationFunctional Constipation: Individualising Assessment and Treatment
Pannemans, J., Masuy, I., & Tack, J. (2020) · Drugs · doi:10.1007/s40265-020-01305-z · Cited by 55
Chronic constipation and abdominal pain: Independent or closely interrelated symptoms?
Wong, M. Y. W., Hebbard, G., Gibson, P. R., & Burgell, R. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14970 · Cited by 49
Laxative Inadequate Relief Survey (LIRS) Group, Neri, L., Conway, P. M., & Basilisco, G. (2014) · Quality of Life Research · doi:10.1007/s11136-014-0886-2 · Cited by 51
Corsetti, M., & Tack, J. F. (2013) · United European Gastroenterology Journal · doi:10.1177/2050640612474446 · Cited by 48
Narcotic Bowel Syndrome and Opioid-Induced Constipation
Szigethy, E., Schwartz, M. B., & Drossman, D. A. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0410-4 · Cited by 46
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders
Camilleri, M., Bueno, L. P., Andresen, V., Ponti, F. D., Choi, M., & Lembo, A. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.029 · Cited by 49
Self-citation2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Cho, Y. S., Lee, Y. J., Shin, J. E., Jung, H., Park, S., Kang, S. J., Song, K. H., Kim, J., Lim, H. C., Park, H. S., et al. (2023) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm23066 · Cited by 53
Beattie, D. T., Armstrong, S. R., Vickery, R. G., Tsuruda, P. R., Campbell, C. B., Richardson, C. L., McCullough, J. L., Daniels, O., Kersey, K., Li, Y.-P., et al. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00025 · Cited by 44
“…and prucalopride, produce robust clinical efficacy in chronic idiopathic constipation patients, have been well tolerated to date, and offer renewed hope for patients experiencing disorders of reduced GI motility (Camilleri et al., 2008; Sanger, 2009; Goldberg et al., 2010; Manabe et al., 2010).”
BackgroundInfluentialProkinetics in the Management of Functional Gastrointestinal Disorders
Quigley, E. M. M. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0593-6 · Cited by 46
Pharmacologic Management of Chronic Constipation
Singh, S., & Rao, S. S. C. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.08.001 · Cited by 47
“Three large phase 3 RCTs have demonstrated efficacy in relieving all aspects of constipation (see Table 2).(37,38) During an open-label continuation for approximately 12 to 24 months, patients’ satisfaction with tegaserod was maintained.”
BackgroundEffect of subcutaneous methylnaltrexone on patient-reported constipation symptoms
Iyer, S. S., Randazzo, B. P., Tzanis, E. L., Schulman, S. L., Zhang, H., Wang, W., & Manley, A. L. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.003 · Cited by 44
Acupuncture for patients with chronic functional constipation: A randomized controlled trial
Zheng, H., Liu, Z., Zhang, W., Chen, M., Zhong, F., Jing, X. ‐., Rong, P., Zhu, W., Wang, F., Liu, Z. ‐., et al. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13307 · Cited by 46
An update on irritable bowel syndrome: from diagnosis to emerging therapies
Chang, J. Y., & Talley, N. J. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283414065 · Cited by 40
Vitton, V., Damon, H., Benezech, A., Bouchard, D., Brardjanian, S., Brochard, C., Coffin, B., Fathallah, N., Higuero, T., Jouët, P., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001080 · Cited by 45
Tack, J., & Corsetti, M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.719497 · Cited by 40
“The safety and tolerability of prucalopride was assessed in all the Phase-II and in the 3 Phase-III pivotal trials, allowing evaluation of 1924 patients [49-51].”
BackgroundMethodInfluentialAndresen, V., Keller, J., Pehl, C., Schemann, M., Preiß, J., & Layer, P. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0751 · Cited by 53
Chronic constipation: new diagnostic and treatment approaches
Lacy, B. E., Levenick, J. M., & Crowell, M. D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12443093 · Cited by 40
“In the study by Camilleri and colleagues [Camilleri et al. 2008], 10 of 411 patients who received prucalopride reported a serious adverse event (SAE) compared with 8 of 209 patients who received placebo.”
BackgroundResultCamilleri, M., & Deiteren, A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903567057 · Cited by 40
“2 Phase III studies There are three pivotal Phase III trials evaluating the efficacy of prucalopride in patients with chronic constipation in whom laxatives did not provide adequate relief (Table 2) [58-60].”
BackgroundMethodInfluentialSelf-citationConstipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
Jadallah, K. A., Kullab, S. M., & Sanders, D. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8898 · Cited by 47
Elobixibat for the treatment of constipation
Wong, B. S., & Camilleri, M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.753056 · Cited by 38
“Prucalopride accelerates transit at all levels of the gut in patients with CIC [12], with clinical trials showing efficacy and safety in CIC [13], even in elderly patients [14].”
BackgroundSelf-citationManagement Strategies for Abdominal Bloating and Distension.
Foley, A., Burgell, R., Barrett, J. S., & Gibson, P. R. (2014) · Europe PMC (PubMed Central) · Cited by 44
Zhu, J., Qian, Y., Pan, J., He, C., Lan, Y., Chen, W.-N., Wang, B., Wei, Z., Li, J., Li, X., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101407 · Cited by 41
2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome
Choi, Y., Youn, Y. H., Kang, S. J., Shin, J. E., Cho, Y. S., Jung, Y. S., Shin, S. Y., Huh, C. W., Lee, Y. J., Koo, H. S., et al. (2025) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm25007 · Cited by 33
“176 177-182 Unlike nonselective 5-HT 4 agonists (cisapride and tegaserod), which are associated with significant interactions with other receptors, leading to adverse cardiovascular events and resulting in withdrawal of these drugs from the market, serious cardiovascular toxicity has not been…”
Assessment and management of constipation in older people
Woodward, S. (2012) · Nursing Older People · doi:10.7748/nop2012.06.24.5.21.c9115 · Cited by 38
A practical approach to diagnosis and management of functional constipation in adults
Bassotti, G., & Villanacci, V. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0698-0 · Cited by 36
“Prucalopride, approved for treatment of constipation at a dose of 2 mg daily (reduced to a starting dose of 1 mg daily in elderly patients), has been shown to be effective in several trials [26].”
BackgroundPrescribing opioids in older people
Huang, A. R., & Mallet, L. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.11.002 · Cited by 36
Childhood constipation: finally something is moving!
Koppen, I. J. N., Lorenzo, C. D., Saps, M., Dinning, P. G., Yacob, D., Levitt, M. A., & Benninga, M. A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1098533 · Cited by 40
Wang, W., Liu, Y., Yang, X., Sun, J., Yue, Z., Lu, D., Zhou, K., Sun, Y., Hou, A., Zang, Z., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.0310 · Cited by 42
Beattie, D. T., Higgins, D. L., Ero, M., Amagasu, S. M., Vickery, R. G., Kersey, K., Hopkins, A., & Smith, J. A. M. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.11.002 · Cited by 36
Shin, J. E., Jung, H., Lee, T. H., Jo, Y., Lee, H., Song, K. H., Hong, S. N., Lim, H. C., Lee, S. J., Chung, S. S., et al. (2016) · Korean Journal of Medicine · doi:10.3904/kjm.2016.91.2.114 · Cited by 34
Potential neuro-immune therapeutic targets in irritable bowel syndrome
Casado‐Bedmar, M., & Keita, Å. V. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820910630 · Cited by 37
Kuo, B., Barnes, C. N., Nguyen, D. D., Shaywitz, D. A., Grimaldi, M., Renzulli, C., Canafax, D. M., & Parkman, H. P. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16344 · Cited by 35
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology
Camilleri, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70837 · Cited by 32
“There is considerable evidence supporting prucalopride’s pharma-codynamic effects, safety, and efficacy in chronic constipation (72); it is approved in most countries, but not in the United States.”
Self-citationAgrawal, L., Korkutata, M., Vimal, S. K., Yadav, M. K., Bhattacharyya, S., & Shiga, T. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107969 · Cited by 34
Videlock, E. J., & Chang, L. (2016) · Wiley eBooks · doi:10.1002/9781119127437.ch65 · Cited by 32
Andresen, V., Pehl, C., Becker, G., Frieling, T., Goebel‐Stengel, M., Gundling, F., Herold, A., Karaus, M., Keller, J., Kim, M., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-1928 · Cited by 37
Constipation in Adults: Diagnosis and Management
Costilla, V. C., & Foxx–Orenstein, A. E. (2014) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-014-0025-8 · Cited by 33
Novel therapies for constipation
Thayalasekeran, S., Ali, H., & Tsai, H.-H. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i45.8247 · Cited by 32
Halland, M., & Talley, N. J. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.207 · Cited by 40
Bazzocchi, G., Giovannini, T., Giussani, C., Brigidi, P., & Turroni, S. (2014) · Techniques in Coloproctology · doi:10.1007/s10151-014-1201-5 · Cited by 32
“opride, a next-generation drug, showed improvement of constipation only in 30–40 % of patients [3, 4].”
BackgroundWang, X., & Camilleri, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i10.1185 · Cited by 33
Self-citationEffect of ICU interventions on gastrointestinal motility
Fruhwald, S. M., & Kainz, J. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e3283356679 · Cited by 32
Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments
Müller-Lissner, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.773972 · Cited by 31
“This holds true for lactulose and macrogol [2], bisacodyl [3,4], sodium picosulfate (SPS) [5], anthraquinones [6,7], lubiprostone [8-10], linaclotide [11] as well as prucalopride [12-14].”
BackgroundThe Mexican consensus on chronic constipation
Remes-Troche, J. M., Coss‐Adame, E., López‐Colombo, A., Amieva‐Balmori, M., Sánchez, R. C., Guindic, L. C., Rendón, R. F., Escudero, O. G., Martínez, M. G., Chávez, M. E. I., et al. (2018) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.05.012 · Cited by 37
Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents
Sainsbury, A., & Ford, A. C. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10387203 · Cited by 32
“In a 12-week phase 3 RCT involving over 600 patients with severe CIC, significantly more patients receiving 2 or 4 mg of prucalopride obtained relief from constipation than with placebo (defined as an average of three or more complete spontaneous bowel movements per week) [Camilleri et al. 2008].”
BackgroundMiner, P. B., Camilleri, M., Burton, D. D., Achenbach, H., Wan, H., Dragone, J., & Mellgard, B. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12832 · Cited by 31
Self-citationUrogenital consequences in ageing women
Doumouchtsis, S. K., & Chrysanthopoulou, E. L. (2013) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.03.007 · Cited by 30
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview
Bokic, T., Storr, M., & Schicho, R. (2015) · Pharmacology · doi:10.1159/000435816 · Cited by 32
Prucalopride: A Review of Its Use in the Management of Chronic Constipation
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0140-1 · Cited by 31
“9 % of prucalopride 2 mg once daily recipients [42, 43, 45] and 2.”
InfluentialUse of prucalopride in adults with chronic idiopathic constipation
Vijayvargiya, P., & Camilleri, M. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1620104 · Cited by 30
Self-citationChronic constipation: from pathophysiology to management
Barbara, G., Barbaro, M. R., Marasco, G., & Cremon, C. (2023) · Minerva Gastroenterology · doi:10.23736/s2724-5985.22.03335-6 · Cited by 35
Serotonergic agents and the irritable bowel syndrome: what goes wrong?
Spiller, R. E. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.003 · Cited by 34
“Most recently a large placebo controlled trial of Prucalopride 4mgs in 620 constipated patients over a seven-week period showed an increase of spontaneous complete bowel movement in 47% compared with 26% on placebo [49].”
BackgroundValidation of a Bowel Function Diary for Assessing Opioid-Induced Constipation
Camilleri, M., Rothman, M. L., Ho, K. F., & Etropolski, M. S. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.431 · Cited by 30
Self-citationShin, A., Acosta, A. J., Camilleri, M., Boldingh, A., Burton, D. D., Ryks, M. D., Rhoten, D. L., & Zinsmeister, A. R. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.012 · Cited by 31
Self-citationEfficacy and safety of prucalopride in adults and children with chronic constipation
Diederen, K., Mugie, S. M., & Benninga, M. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.996547 · Cited by 29
“In contrast with adult studies [70-72], these data implicate that prucalopride is not effective in children, which can be interpreted as a possible different underlying pathophysiological mechanism.”
BackgroundMethodResultInfluentialEswaran, S. L., Guentner, A. S., & Chey, W. D. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2014.20.2.141 · Cited by 30
Prucalopride succinate for the treatment of constipation: an update
Bassotti, G., Gambaccini, D., & Bellini, M. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1129897 · Cited by 30
Wang, Y., Liu, Y., Zhou, K., Bauer, B. A., Liu, B., Su, T., Mo, Q., & Liu, Z. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819881859 · Cited by 28
Metadata
- Authors
- Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Camilleri, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-29
- Volume
- 358
- Issue
- 22
- Pages
- 2344-2354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068454300
- Cited by
- 576
- References
- 36
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
- FWCI
- 45.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.